Course No 4: Chronic Complications of Diabetes
Chronic Complications of Diabetes:
Definition
Pathogenesis
Diagnosis
Treatment
Microvascular Complications in Diabetes:
Retinopathy
Nephropathy
Neuropathy
Macrovascular Complications in Diabetes:
Coronary Artery Disease
Cerebrovascular Disease
Peripheral Vascular Disease
Diabetic Foot
Characterized by thickening of the basement membrane of small blood vessels and capillaries.
Types:
Diabetic Retinopathy
Diabetic Nephropathy
Diabetic Neuropathy
Associated with atherosclerosis, leading to:
Hardening of arteries
Types:
Coronary Artery Disease
Cerebrovascular Disease
Peripheral Vascular Disease
A significant issue related to complications.
Increasingly common as more people live longer with diabetes.
Affect nearly all organ systems of the body.
Occur in both Type 1 and Type 2 diabetes, generally within 5 to 10 years following hyperglycemia.
Polyol Pathway:
Glucose converted to sorbitol and fructose via NADPH pathway.
Hexosamine Pathway:
Alters various cell metabolic functions.
AGE Pathway (Advanced Glycation End Products):
Contributes to vascular and nerve damage.
AGEs: Advanced Glycation End products
eNOS: Endothelial Nitric Oxide Synthase
NF-kB: Nuclear Factor Kappa B
ROS: Reactive Oxygen Species
TGF-β: Transforming Growth Factor Beta
PAI-1: Plasminogen Activator Inhibitor-1
ET-1: Endothelin-1
Increased risk of blindness in working-age adults by 2-4 times.
Significant mortality rates related to diabetic conditions.
Leading causes of end-stage renal disease and non-traumatic amputations due to diabetic complications.
A specific microvascular complication of diabetes.
Leading cause of blindness in adults.
Longer duration of diabetes
Chronic hyperglycemia
Frequent hypoglycemia
Pregnancy
Smoking
Fundus examination (Ophthalmoscopy)
Fluorescein Angiography for preclinical changes.
Non-proliferative Diabetic Retinopathy (NPDR):
Mild
Moderate
Severe
Proliferative Diabetic Retinopathy (PDR)
Diabetic Maculopathy
Advanced Diabetic Eye Diseases:
Vitreous/Preretinal Hemorrhage
Retinal Detachment
Rubeosis Iridis
Neovascular Glaucoma
Blurred vision, Floaters, Loss of vision, Shadows in vision, Eye pain.
T1DM: Annually, starting 5 years post-onset.
T2DM: Every 1-2 years from diagnosis.
For Proliferative Diabetic Retinopathy:
Laser therapy (panretinal photocoagulation)
Intraocular pharmacological intervention (VEGF antagonists)
For Diabetic Macular Edema:
Focal laser therapy
Vitrectomy if necessary
Progressive increase in proteinuria leading to declining renal function, risking end-stage renal disease.
Long-standing diabetes
Family history of hypertension and cardiovascular diseases
Hyperglycemia
Hypertension
Male Gender
Smoking
Diffuse Glomerular Basement Membrane Thickening: Most common.
Nodular Form (Kimmelstiel-Wilson Lesion): Accumulation of specific materials in glomeruli.
Control Measures:
Glycemic control
Blood pressure management
ACE inhibitors or ARBs for patients with urinary albumin excretion ≥30 mg/24 h.
Sensorimotor Neuropathy
Proximal Motor Neuropathy
Acute Mononeuropathy
Autonomic Neuropathy
Improving life quality by reducing symptoms and sequelae.
Up to 50% may be asymptomatic.
Numbness, Tingling, Sharp pains, Loss of balance.
Complications may include painless ulceration.
10-g monofilament test for all patients at diagnosis and at least annually.
Tight glycemic control
Vitamin B supplementation
Alpha-lipoic acid
A significant threat in diabetes, affecting heart and vascular systems.
Advancing age, Chronic hyperglycemia, Dyslipidemia, Obesity, Sedentary lifestyle.
4-fold increase in risk of cardiovascular events compared to non-diabetic individuals.
Increased risk for strokes and lower-extremity amputations.
Assess for atypical cardiovascular symptoms.
Evaluate for cerebrovascular and peripheral disease.
Major causes of morbidity and disability stemming from neuropathy and vascular disease.
Annual foot exams recommended for all diabetes patients.
Tight glycemic control, Infection treatment, Diabetic arterial disease management, Proper footwear education, and supportive therapies.